 LOS ANGELES--BUSINESS WIRE--- CDXC ataxia--ChromaDex Corp. NASDAQ:CDXC today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDexs proprietary Niagen ingredient patented nicotinamide riboside, or NR in patients with ataxia-telangiectasia AT, a rare, inherited neurodegenerative disorder characterized by premat 